As the patent for semaglutide nears its end, Novo Nordisk’s dominance in the weight-loss market is being challenged. The lawsuits could pave the way for cheaper generics, catering to India’s vast population battling obesity.
Recent Posts
- Silver prices fall in India as strong dollar, rising oil prices, and Fed rate fears pressure metals
- Gold rate drops on MCX due to profit booking amid elevated crude oil prices; focus remains on potential US-Iran talks
- OnEMI Technology Solutions IPO: Price band set at ₹162-171 per share; check issue detail, key dates, more
- Q4 results 2026: Coal India to Varun Beverages among companies to declare Q4 results today; check full list here
- Stock market today: Gift Nifty signals gap-up opening; India VIX, oil to gold, silver rates — 8 stocks to buy or sell